<DOC>
	<DOCNO>NCT01164215</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fluorouracil , oxaliplatin , leucovorin calcium , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug , combination chemotherapy , may kill tumor cell . Studying sample blood laboratory patient cancer receive fluorouracil combination oxaliplatin leucovorin calcium may help doctor learn fluorouracil work body patient respond treatment . PURPOSE : This phase I trial study biomarker-guided fluorouracil treat patient colorectal cancer receive combination chemotherapy .</brief_summary>
	<brief_title>Biomarker-Guided Fluorouracil Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine whether 4 course pharmacokinetic ( PK ) -guided 5-fluorouracil chemotherapy improve ability achieve target area curve ( 20 25 mg*hr/L ) patient colorectal cancer receive mFOLFOX6 chemotherapy compare historical non-PK-guided therapy patient treat similar FOLFOX regimen . Secondary - To determine compare incidence neutropenia diarrhea patient treat regimen . OUTLINE : This multicenter study . - Standard mFOLFOX6 ( course 1 ) : Patients receive fluorouracil IV bolus 1-5 minute follow fluorouracil IV continuously 46 hour , oxaliplatin IV 2 hour , leucovorin calcium IV 2 hour day 1 . Patients undergo plasma sample collection periodically study pharmacokinetic ( PK ) -guided fluorouracil dose determination course 2-4 . - PK-guided mFOLFOX6 ( course 2-4 ) : Patients receive fluorouracil bolus , oxaliplatin , leucovorin calcium course 1 . Patients also receive fluorouracil* IV continuously determine PK-guided analysis . NOTE : *The continuous infusion fluorouracil dose adjustment calculate base result PK plasma concentration correspond AUC precede course .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm colorectal cancer Patients schedule receive mFOLFOX6 ( adjuvant set metastatic disease ) part chemotherapy regimen PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy &gt; 6 month ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Serum creatinine ≤ 1.5 mg/dL Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN ( ≤ 5 time ULN presence liver metastasis ) Fertile patient must use effective contraception Negative pregnancy test Not pregnant nursing No serious concomitant systemic disorder , include active infection , opinion investigator , would compromise patient 's safety ability complete study No alter mental status preclude understand informed consent process and/or completion necessary study Must able follow protocol requirement give informed consent PRIOR CONCURRENT THERAPY : See Disease Characteristics Concurrent bevacizumab allow No concurrent warfarin ( Coumadin® ) Concurrent enoxaparin ( Lovenox® ) allow No concurrent theophylline aminophylline No chocolate begin 12 hour day 1 course end course 's fluorouracil continuous IV</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>neutropenia</keyword>
	<keyword>diarrhea</keyword>
	<keyword>stage I colon cancer</keyword>
	<keyword>stage II colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage I rectal cancer</keyword>
	<keyword>stage II rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>